Ganymed Pharmaceuticals

Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission to revolutionize cancer treatment by developing a new class of therapeutic agents called Ideal Monoclonal Antibodies (IMABs). The uniqueness of IMABs lies in their high selectivity for proteins present on tumor cells without binding to healthy cells. This unparalleled tumor cell specificity enables IMABs to selectively target cancer cells, effectively killing tumor cells without harming normal healthy tissue. As a result, they can be administered at optimal doses, offering a broad therapeutic window with a reduced risk of side effects.